Additional milestone payment.

No definition available.

Name:	biib_AdditionalMilestonePayment
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Estimated additional payments upon achievement of development and commercial milestones.

+ References

No definition available.

+ Details

Name:	biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Expected additional milestone payments when meeting certain sales threshold.

+ References

No definition available.

+ Details

Name:	biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Expected license fee and regulatory milestone payments.

+ References

No definition available.

+ Details

Name:	biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Investment In Common Stock, Shares Purchased

+ References

No definition available.

+ Details

Name:	biib_InvestmentInCommonStockSharesPurchased
Namespace Prefix:	biib_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

License Fee

+ References

No definition available.

+ Details

Name:	biib_LicenseFee
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of royalties as per collaboration.

+ References

No definition available.

+ Details

Name:	biib_PercentageOfRoyaltiesAsPerCollaboration
Namespace Prefix:	biib_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Purchase of common stock

+ References

No definition available.

+ Details

Name:	biib_Purchaseofcommonstock
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Term Of Collaboration Agreement

+ References

No definition available.

+ Details

Name:	biib_TermOfCollaborationAgreement
Namespace Prefix:	biib_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Total payment to enter collaboration agreement

+ References

No definition available.

+ Details

Name:	biib_Totalpaymenttoentercollaborationagreement
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Total upfront and milestone payments made to collaborative partner.

+ References

No definition available.

+ Details

Name:	biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Upfront Payment For Collaboration Agreement

+ References

No definition available.

+ Details

Name:	biib_UpfrontPaymentForCollaborationAgreement
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.

+ References

No definition available.

+ Details

Name:	us-gaap_PrepaidExpenseAndOtherAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=biib_SPINRAZAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=biib_BIIB115Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=biib_SOD1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=biib_BIIB080Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=biib_QALSODYMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative and Other Relationships - Ionis (Details) - USD ($) shares in Millions, $ in Millions	1 Months Ended					12 Months Ended
	Dec. 31, 2019	Jun. 30, 2018	Dec. 31, 2017	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2018
Collaborative arrangements and non-collaborative arrangement transactions
Cost of sales, excluding amortization and impairment of acquired intangible assets						$ 2,533.4	$ 2,278.3	$ 2,109.7
Research and development						2,462.0	2,231.1	2,501.2
Ionis Pharmaceuticals
Collaborative arrangements and non-collaborative arrangement transactions
Term of collaboration agreement		10 years		6 years
Total payment to enter collaboration agreement		$ 1,000.0
Upfront payment for collaboration agreement		$ 375.0
Investment in common stock, shares purchased (in shares)		11.5
Purchase of common stock		$ 625.0
Prepaid research and discovery services		50.9
Research and development		324.1				7.5	10.0	22.5
Estimated additional payments upon achievement of development and commercial milestones									$ 260.0
Upfront and milestone payments made to collaborative partner			$ 25.0
Expected additional milestone payments when certain sales threshold is met									$ 800.0
License fee				$ 70.0	$ 70.0
Expected license fee and regulatory milestone payments				$ 130.0	$ 130.0
Research and development expense asset acquired	$ 45.0
Additional milestone payment	155.0
Ionis Pharmaceuticals \| SPINRAZA
Collaborative arrangements and non-collaborative arrangement transactions
Cost of sales, excluding amortization and impairment of acquired intangible assets						240.2	243.1	267.1
Ionis Pharmaceuticals \| BIIB115
Collaborative arrangements and non-collaborative arrangement transactions
Upfront payment for collaboration agreement								60.0
Ionis Pharmaceuticals \| SOD1
Collaborative arrangements and non-collaborative arrangement transactions
Research and development							$ 17.0	$ 10.0
Estimated additional payments upon achievement of development and commercial milestones	55.0
Ionis Pharmaceuticals \| BIIB080
Collaborative arrangements and non-collaborative arrangement transactions
Research and development expense asset acquired	10.0
Ionis Pharmaceuticals \| QALSODY
Collaborative arrangements and non-collaborative arrangement transactions
Research and development						$ 16.0
Estimated additional payments upon achievement of development and commercial milestones	$ 20.0
Ionis Pharmaceuticals \| Minimum
Collaborative arrangements and non-collaborative arrangement transactions
Estimated additional payments upon achievement of development and commercial milestones		125.0
Ionis Pharmaceuticals \| Minimum \| SPINRAZA
Collaborative arrangements and non-collaborative arrangement transactions
Percentage of royalties as per collaboration						11.00%
Ionis Pharmaceuticals \| Minimum \| QALSODY
Collaborative arrangements and non-collaborative arrangement transactions
Percentage of royalties as per collaboration						11.00%
Ionis Pharmaceuticals \| Maximum
Collaborative arrangements and non-collaborative arrangement transactions
Estimated additional payments upon achievement of development and commercial milestones		$ 270.0
Ionis Pharmaceuticals \| Maximum \| SPINRAZA
Collaborative arrangements and non-collaborative arrangement transactions
Percentage of royalties as per collaboration						15.00%
Ionis Pharmaceuticals \| Maximum \| QALSODY
Collaborative arrangements and non-collaborative arrangement transactions
Percentage of royalties as per collaboration						15.00%